Menu
Menu
London, United Kingdom, 13 May 2026 – SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England’s leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of NHS England’s ‘revolutionary blood test-first’ program.
Synnovis, a major provider for England’s South East Genomic Medicine Service, worked with SOPHiA GENETICS to launch the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDMTM. This innovative test, originally developed by Memorial Sloan Kettering Cancer Center in New York, detects actionable genomic alterations from a single blood draw and leverages state-of-the-art Ai to analyze circulating tumor DNA (ctDNA) in a minimally invasive manner.
The new blood-based test offered by Synnovis can help fast-track cancer patients to receive targeted therapy up to two weeks earlier, while helping some avoid further tests and invasive treatments such as chemotherapy.
Following the successful pilot program, Synnovis is already supporting approximately 400 patients per month with ctDNA liquid biopsy testing and is demonstrating the real-world impact of this advanced care. In one case, a patient with suspected advanced lung cancer was able to receive a ctDNA-informed personalised treatment plan within just two weeks. In another case, providers used SOPHiA DDMTM to identify new genetic variants for a patient who had been living with breast cancer for more than 15 years, unlocking additional treatment options and potential eligibility for clinical trials.
Synnovis and SOPHiA GENETICS anticipate that the application will be used to test approximately 7,000 breast and lung cancer patients annually, or roughly one third of all ctDNA tests in England, as the demand for liquid biopsy testing increases.
Persephone du Parcq, MSc., Lead Translational Scientist, Synnovis, said: “Liquid biopsy testing simplifies how we generate genomic insights. A routine blood draw can reveal information from multiple tumour sites and speed up delivery of results to the patients. It also broadens access for patients who cannot tolerate invasive procedures or travel to specialist hospitals. As adoption increases, this approach will substantially expand the reach and impact of genomic testing services, and we anticipate economic savings for healthcare providers and better outcomes for greater numbers of patients.”
Ross Muken, President, SOPHiA GENETICS, said: “Synnovis plays a vital role in delivering genomic testing services to patients across South East England, and this partnership reflects what becomes possible when world-class pathology infrastructure meets scalable Ai-driven analysis. With roughly one third of all ctDNA testing in England expected to run through this programme, we see this as a defining moment for liquid biopsy at scale within the NHS , and a model for how health systems in Europe can make precision oncology accessible.
Beyond accelerating targeted treatments, MSK-ACCESS® powered with SOPHiA DDMTM provides Synnovis with the flexibility to incorporate additional indications as they are introduced into future NHS cancer screening programs. It also utilizes a matched tumor-normal approach as well as technology from AccuGenomics® to improve accuracy and avoid false positives.
Leading laboratories like Synnovis are helping bring NHS England’s ‘blood test-first’ approach to scale through innovative solutions, contributing to a sustainable, data-driven approach to cancer care across the United Kingdom. By strengthening its genomic testing infrastructure, Synnovis joins a growing network of NHS institutions using SOPHiA GENETICS’ technology to conduct local analysis, maintain alignment with NHS data-security standards, and support the operational model of distributed analysis hubs.
To learn more about how Synnovis deployed ctDNA testing for the patients it serves, view a webinar presented by one of the laboratory’s lead scientists.
SOPHiA GENETICS will be attending the International Society for Liquid Biopsy Annual Meeting (ISLB) in Madrid, Spain! We look forward to connecting with leaders and innovators to discuss the evolving role of data in shaping the future of healthcare. Meet us at Booth #21.
More information is coming soon!
SOPHiA GENETICS is heading to the European Society for Medical Oncology Congress (ESMO) 2026 in Madrid, Spain. Meet our team at Booth #8068 to learn how we are helping advance precision medicine through intelligent analytics and collaborative innovation.
More updates on our participation and activities will be announced soon!
Join SOPHiA GENETICS at the European Congress of Pathology (ECP) 2026 in Stockholm, Sweden. We are excited to engage with the pathology community and share how our technology helps transform complex data into practical insights.
Visit our page again shortly for more information!
SOPHiA GENETICS will be at the Association for Molecular Pathology Europe Congress (AMP Europe) 2026 in Tallinn, Estonia. Find us at Booth #13 where our team of experts will be ready to discuss how SOPHiA DDM™ platform is helping laboratories and healthcare institutions advance data-driven oncology insights.
Come explore our partnership with the Memorial Sloan Kettering Cancer Center and our latest updates across the MSK solutions portfolio, including enhanced CNV detection with tumor purity and ploidy analysis in MSK-IMPACT® Flex, and new capabilities in MSK-ACCESS® including MSI and ctDNA fraction, now available on GEN2.
Also learn more about OncoKB™ which is now fully embedded in SOPHiA DDM™ oncology workflows, and what that means for somatic variant interpretation in practice.
Industry Symposium
Join our Industry Symposium to explore how combining MSK-IMPACT® Flex and MSK-ACCESS® on the SOPHiA DDM™ Platform unlocks deeper, more complete oncology insights. From real-world use cases to the latest liquid biopsy enhancements, this is a must-attend session for those looking to take their genomic profiling further.
Monday, 15 June | 2:30pm – 3:30pm | Ballroom
Integrating tissue and liquid biopsy for in-depth precision oncology insights
Dr. Maria De Bonis, Biologist and Health Manager, Fondazione Policlinico A. Gemelli IRCCS, Italy
Lina Li, Product Director of Solid Tumors, SOPHiA GENETICS
MTAP deletion is rapidly emerging as a clinically actionable biomarker across multiple tumor types, frequently associated with a poor prognosis. While this is driving new therapeutic opportunities, it also exposes a major challenge for precision oncology trials: accurately testing for difficult and novel biomarkers. In Europe, especially, this gap continues to delay clinical trial enrolment and slow therapeutic progress.
In this webinar, we will explore how SOPHiA GENETICS, in partnership with ARC Regulatory, is addressing these challenges by implementing a comprehensive genomic profiling assay to enable biomarker identification and patient enrolment for clinical trials across Europe. By combining SOPHiA GENETICS’ AI-powered technology with ARC Regulatory’s expertise in assay implementation and workflow validation, we accelerate CTA development in instances such as MTAP deletion. Together, we aim to reduce regulatory risk in clinical research programs, shorten timelines for clinical trial recruitment, and broaden clinical trial recruitment in Europe.
Join us to gain insights into the nuances of European clinical trial testing and how robust genomic solutions can advance precision oncology research and ultimately improve patient outcomes.
Speakers:
Join SOPHiA GENETICS at the European Human Genetics Conference (ESHG) 2026 in Gothenburg, Sweden! Find us at Booth #214, where our experts will be ready to discuss the latest in genomic testing for rare and inherited disease research.
Explore our newest applications, including enhanced clinical and whole exomes (WES), whole genome sequencing (WGS), and our extended pharmacogenomics solution, all connected through a single sample-to-report workflow with seamless EHR and LIMS integration of the SOPHiA DDM™ Platform linked with Alamut™ Visual Plus.
Come discover how SOPHiA DDM™ and Alamut™ Visual Plus can support your lab from sample to clinical insight.
Corporate Session
Join our Corporate Session as leading European laboratories share practical approaches to scaling genomic workflows across transcriptomics, WES, and WGS, all powered with our SOPHiA DDM™ Platform and Alamut™ Visual Plus.
Saturday, 13 June | 12:15pm – 1:30pm | Room A6
New approaches to molecular interpretation in clinical genomics: From transcriptomics to exome and genome sequencing
Minna Paavola, Clinical Laboratory Geneticist, Turku University Hospital, Finland
Tobias Bethge, PhD, Molecular Geneticist, Genetica AG, Switzerland
Gorka Alkorta-Aranburu, PhD, Laboratory Director, Clínica Universidad de Navarra, Spain
Sevana Yaghoubian, MSc, Senior Director of Product Management, SOPHiA GENETICS
Poster Presentations
Comprehensive genome analysis with SOPHiA DDM™ for low-pass and 30x WGS
- presented by Izabela Matyszczak, PhD, Technical Product Management Expert - Genomic Research at SOPHiA GENETICS
Sunday, 14 June | 12:45pm to 1:45pm | P20.159.C
Excelsa: A variant prioritization algorithm integrating variant- and phenotype-level evidence
- presented by Giulia Muzio, PhD, Bioinformatician - Tertiary Analysis at SOPHiA GENETICS
Sunday, 14 June | 3:45pm to 4:45pm | P15.094.D
Meet the Experts Networking Session
Join us at our booth to connect with our genomics experts and take part in engaging conversations with peers and industry professionals.
Saturday, 13 June | 3:45pm to 4:45pm | Booth #214
The future of precision medicine is coming to San Sebastián!
The EMEA Innovation Summit by SOPHiA GENETICS explores how precision medicine is scaling today, and what breakthroughs will shape clinical care tomorrow.
Following the success of our 2025 edition in Rolle, we’re thrilled to host the next SOPHiA GENETICS Innovation Summit at the iconic Real Sociedad Arena, a venue that captures the energy, innovation, and collaboration that define our community.
This year’s agenda is set to dive deep into innovation, from AI-driven discovery and liquid biopsy advancements to collaborative approaches in oncology and clinical genomics. Expect thought-provoking sessions, impactful discussions, and cross-industry networking designed to accelerate innovation in healthcare.
Over two days, the event brings together:
Together, we connect insights with real-world impact bridging today’s scalable platforms with tomorrow’s clinical breakthroughs.
The day will begin with a focus on scalability and operational maturity, tackling the growing challenges of data volume and complexity while building robust end-to-end workflows. Through AI-driven insights, we’ll explore how to accelerate the global adoption of precision medicine. In the afternoon, the spotlight shifts to future-facing clinical innovation, diving into next-generation data modalities and their applications across solid tumors, liquid biopsy, blood cancers, and germline analysis. Bringing it all together, the sessions highlight real-world clinical studies, emerging technologies, and pharma perspectives, showcasing how advanced analytics are translating into meaningful clinical impact.
Fill out the form to secure your spot!
Do you have any questions or require further assistance? Please get in touch with us!
We’re pleased to welcome AZ Delta Roeselare in Belgium, one of the largest hospitals in Flanders, to the SOPHiA GENETICS community as they expand their precision medicine capabilities by adopting a broad range of applications on the SOPHiA DDM™ Platform.
Through this adoption, AZ Delta Roeselare is advancing data-driven medicine across both blood and solid tumor indications, leveraging germline and somatic solutions across SOPHiA DDM™ to support insights into complex diseases. By consolidating diverse genomic workflows within a single platform, the hospital is strengthening multidisciplinary collaboration and streamlining the analysis of complex genomic data across multiple indications.
We’re proud to support their work as part of the SOPHiA GENETICS community.
We are glad to return to Swiss Biotech Day 2026, where you will have the chance to meet our leadership team for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine
The SOPHiA GENETICS team is thrilled to see you at our Fireside chat on Monday, May 4th from 15.30 to 16.15, in Room Delhi – Level 0.
“Liquid Biopsy at a Tipping Point in Precision Oncology”
Join Philippe Menu, MD, PhD, MBA, EVP, Chief Medical & Product Officer, SOPHiA GENETICS, Elena Guerini Rocco, MD, Director of the Oncology Genetics Unit, IEO – Istituto Europeo di Oncologia, and Thomas di Maio, EU/Canada Diagnostic Lead, AstraZeneca for an insightful conversation about the liquid biopsy movement.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.